# Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

> **NCT00954460** · — · APPROVED_FOR_MARKETING · sponsor: **Shire**

## Conditions studied

- Gaucher Disease, Type 1

## Interventions

- **DRUG:** velaglucerase alfa

## Key facts

- **NCT ID:** NCT00954460
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954460, "Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00954460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*